tenapanor (Ibsrela) Report issue

Small molecule Approved FDA First in Class
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Tenapanor is an inhibitor of the sodium-proton (Na(+)/H(+)) exchanger NHE3 and reduces sodium absorption in the GI tract, thus increasing intestinal fluid. Ardelyx has completed Phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C) and submitted a new drug application to the U.S. Food and Drug Administration for the treatment of patients with IBS-C. In addition, tenapanor successfully completed phase III clinical trial for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and RDX013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease.   NCATS

Chemistry

  • SMILES: CN1Cc2c(Cl)cc(Cl)cc2[C@H](c2cccc(S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c3cccc([C@@H]4CN(C)Cc5c(Cl)cc(Cl)cc54)c3)c2)C1
  • InChIKey: DNHPDWGIXIMXSA-CXNSMIOJSA-N
  • Mol. Mass: 1145.07
  • ALogP: Missing data
  • ChEMBL Molecules:
    tenapanor  
    tenapanor hydrochloride  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Discontinued
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

azd1722 | azd-1722 | azd-1722 hydrochloride | rdx5791 | rdx-5791 | tenapanor | tenapanor hydrochloride

Organizations (6)

Research & Development (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (2)


 

Constipation

Irritable Bowel Syndrome (approved 2019)

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Chronic Kidney Disease-Mineral and Bone Disorder (Phase 4)

Constipation (Phase 3)

Diabetes Mellitus, Type 2 (Phase 2)

Healthy Volunteers (Phase 1)

Hyperphosphatemia (Phase 4)

Irritable Bowel Syndrome (Phase 4)

Kidney Failure, Chronic (Phase 4)

Renal Insufficiency, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 32
  • # of Trial Organizations: 6

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue